Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $86.22 +1.35%
Revenue Growth %: +8.4%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
NLY, CP, RUSHA, More
Revenue Growth %: +8.4%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $0.46, $0.21 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $225 million versus the consensus estimate of $222.98 million.
GUIDANCE:
Haemonetics sees FY2022 EPS of $2.60-$3.00, versus the consensus of $2.56.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plexus Corp (PLXS) Tops Q2 EPS by 7c
- VIST Financial Corp. (VIST) Misses Q1 EPS by 19c
- ESSA Bancorp (ESSA) Tops Q2 EPS by 13c
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
